European Academy of Allergy and Clinical Immunology (EAACI) Congress

BioCryst will attend the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Congress from June 12 – June 15, 2026.

  • Safety, Tolerability, Immunogenicity, and Pharmacokinetics of BCX17725: Single and Multiple Ascending Dose
    SID | 2026 | NS
  • Preclinical Characterization of BCX17725, a Potent Inhibitor of KLK5 and KLK14, for the Treatment of Netherton Syndrome
    SID | 2026 | NS
  • Long-Term, Sustained, Robust Hereditary Angioedema Attack Suppression with Navenibart Administered Every 3 and 6 Months: ALPHA-SOLAR Interim Results
    AAAAI | 2026 | HAE
  • Navenibart Demonstrates Durable Efficacy and Tolerability Across Biological Sexes: Subgroup Analysis from the ALPHA-STAR Trial
    AAAAI | 2026 | HAE
  • Navenibart Delays Time to First Attack in Hereditary Angioedema: Results from ALPHA-STARĀ 
    AAAAI | 2026 | HAE

Have questions about any of our medicines that are approved or in development, or would you like to be connected with an MSL?

Have questions about our company?